Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
Myriad Genetics (NASDAQ: MYGN) and Lumea Inc. have announced a collaboration to integrate Myriad's molecular diagnostic tests - Prolaris Prostate Cancer Test and MyRisk Hereditary Cancer Test - into Lumea's digital pathology platform, BxLink.
The integration aims to streamline test ordering and delivery processes, enabling healthcare providers to electronically manage Prolaris and MyRisk tests through BxLink. This automation is expected to reduce errors and deliver results in under 10 days after specimen collection.
The Prolaris test, which is included in NCCN Guidelines, assesses prostate cancer aggressiveness for treatment decisions, while MyRisk evaluates 48 genes associated with hereditary cancer risk. The collaboration focuses on delivering precision-based insights efficiently to support informed decision-making by patients and providers.
Myriad Genetics (NASDAQ: MYGN) e Lumea Inc. hanno annunciato una collaborazione per integrare i test diagnostici molecolari di Myriad - Prolaris Prostate Cancer Test e MyRisk Hereditary Cancer Test - nella piattaforma di patologia digitale di Lumea, BxLink.
L'integrazione ha l'obiettivo di semplificare i processi di ordinazione e consegna dei test, consentendo ai fornitori di assistenza sanitaria di gestire elettronicamente i test Prolaris e MyRisk tramite BxLink. Si prevede che questa automazione riduca gli errori e consegni i risultati in meno di 10 giorni dopo il prelievo del campione.
Il test Prolaris, incluso nelle linee guida NCCN, valuta l'aggressività del cancro alla prostata per le decisioni di trattamento, mentre MyRisk esamina 48 geni associati al rischio di cancro ereditario. La collaborazione si concentra sulla fornitura di approfondimenti basati sulla precisione in modo efficiente per supportare il processo decisionale informato di pazienti e fornitori.
Myriad Genetics (NASDAQ: MYGN) y Lumea Inc. han anunciado una colaboración para integrar las pruebas de diagnóstico molecular de Myriad - Prolaris Prostate Cancer Test y MyRisk Hereditary Cancer Test - en la plataforma de patología digital de Lumea, BxLink.
La integración tiene como objetivo simplificar los procesos de pedido y entrega de pruebas, permitiendo a los proveedores de salud gestionar electrónicamente las pruebas de Prolaris y MyRisk a través de BxLink. Se espera que esta automatización reduzca errores y proporcione resultados en menos de 10 días después de la recolección de muestras.
La prueba Prolaris, que está incluida en las Guías NCCN, evalúa la agresividad del cáncer de próstata para decisiones de tratamiento, mientras que MyRisk evalúa 48 genes asociados con el riesgo de cáncer hereditario. La colaboración se centra en ofrecer información basada en precisión de manera eficiente para apoyar la toma de decisiones informadas por parte de pacientes y proveedores.
Myriad Genetics (NASDAQ: MYGN)와 Lumea Inc.가 Myriad의 분자 진단 검사인 Prolaris Prostate Cancer Test와 MyRisk Hereditary Cancer Test를 Lumea의 디지털 병리학 플랫폼인 BxLink에 통합하기 위한 협력 관계를 발표했습니다.
이 통합은 검사 주문 및 배송 프로세스를 간소화하고, 의료 제공자가 BxLink를 통해 Prolaris 및 MyRisk 검사를 전자적으로 관리할 수 있도록 하는 것을 목표로 하고 있습니다. 이러한 자동화는 오류를 줄이고 샘플 수집 후 10일 이내에 결과를 제공할 것으로 예상됩니다.
Prolaris 검사는 NCCN 지침에 포함되어 있으며, 치료 결정을 위한 전립선암의 공격성을 평가하고, MyRisk는 유전적 암 위험과 관련된 48개 유전자를 평가합니다. 이 협력은 환자와 제공자의 정보에 기반한 의사 결정을 지원하기 위해 정밀한 통찰력을 효율적으로 제공하는 데 초점을 맞추고 있습니다.
Myriad Genetics (NASDAQ: MYGN) et Lumea Inc. ont annoncé une collaboration pour intégrer les tests de diagnostic moléculaire de Myriad - Prolaris Prostate Cancer Test et MyRisk Hereditary Cancer Test - dans la plateforme de pathologie numérique de Lumea, BxLink.
Cette intégration vise à simplifier les processus de commande et de livraison des tests, permettant aux prestataires de soins de santé de gérer électroniquement les tests Prolaris et MyRisk via BxLink. On s'attend à ce que cette automatisation réduise les erreurs et fournisse les résultats en moins de 10 jours après la collecte des échantillons.
Le test Prolaris, qui est inclus dans les directives NCCN, évalue l'agressivité du cancer de la prostate pour les décisions de traitement, tandis que MyRisk évalue 48 gènes associés au risque de cancer héréditaire. La collaboration se concentre sur la fourniture d'aperçus basés sur la précision de manière efficace pour soutenir la prise de décision éclairée des patients et des prestataires.
Myriad Genetics (NASDAQ: MYGN) und Lumea Inc. haben eine Zusammenarbeit angekündigt, um die molekularen Diagnosetests von Myriad - Prolaris Prostate Cancer Test und MyRisk Hereditary Cancer Test - in die digitale Pathologie-Plattform von Lumea, BxLink, zu integrieren.
Die Integration zielt darauf ab, die Prozesse zur Bestellung und Lieferung von Tests zu optimieren, wodurch es medizinischen Anbietern ermöglicht wird, die Prolaris- und MyRisk-Tests elektronisch über BxLink zu verwalten. Diese Automatisierung soll Fehler reduzieren und Ergebnisse innerhalb von 10 Tagen nach der Probenentnahme liefern.
Der Prolaris-Test, der in den NCCN-Leitlinien enthalten ist, bewertet die Aggressivität von Prostatakrebs für Behandlungsentscheidungen, während MyRisk 48 Gene evaluates, die mit dem Risiko erblichen Krebses zusammenhängen. Die Zusammenarbeit konzentriert sich darauf, präzise Einblicke effizient zu liefern, um die informierte Entscheidungsfindung von Patienten und Anbietern zu unterstützen.
- Integration expected to reduce result delivery time to under 10 days
- Prolaris test included in NCCN Clinical Practice Guidelines
- Streamlined workflow automation likely to reduce operational costs and errors
- None.
Insights
The strategic partnership between Myriad Genetics and Lumea marks a pivotal advancement in molecular diagnostic testing delivery, with significant implications for market positioning and operational efficiency. The integration of Prolaris and MyRisk tests into BxLink's digital pathology platform addresses several critical market needs:
Market Position Enhancement: The inclusion of Prolaris in NCCN Guidelines strengthens its market position and typically leads to broader insurance coverage and increased adoption rates. This integration could accelerate test adoption by removing workflow barriers and improving accessibility.
Operational Excellence: The digital transformation promises substantial operational benefits:
- Reduction in result delivery time to under 10 days, potentially increasing competitive advantage
- Streamlined electronic ordering and tracking, reducing manual errors and administrative costs
- Enhanced workflow efficiency for healthcare providers, potentially driving higher test volumes
Strategic Value: This collaboration positions Myriad strategically in the evolving precision medicine landscape:
- Integration with digital pathology platforms is becoming increasingly critical for molecular diagnostic companies
- Improved accessibility could drive higher adoption of both Prolaris and MyRisk tests
- The partnership could lead to increased market share in the competitive molecular diagnostics sector
The integration represents a significant step toward modernizing Myriad's test delivery infrastructure, potentially leading to improved revenue streams through increased test volumes and operational cost savings. The focus on workflow optimization and faster result delivery aligns with healthcare providers' needs for efficient, integrated diagnostic solutions.
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™.
This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered directly within BxLink’s intuitive platform. By replacing manual processes, the integration will reduce errors and aims to deliver molecular testing results to clinicians in an average of under 10 days after specimen collection.
“Clinicians need ready access to molecular diagnostic tools at the point of care to improve cancer outcomes,” said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. “Prolaris — included in the recent NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer (NCCN Guidelines®)i — quantifies prostate cancer aggressiveness to guide treatment decisions at cancer diagnosis, while MyRisk evaluates 48 genes associated with hereditary cancer risk to guide treatments and identify risks to family members. This collaboration with Lumea ensures precision-based insights are delivered in a timely fashion when they’re needed most to empower patients and providers to make informed decisions.”
“This integration simplifies workflows for physicians,” said Jim Pack, CEO of Lumea. “With fewer clicks and reduced data entry, clinicians can seamlessly order Myriad’s advanced tests, access actionable results within the platform they trust, and deliver personalized care. These insights can unlock advanced treatment options, targeted therapies, and clinical trials, driving improved patient outcomes.”
About Lumea
Lumea is the U.S. leader in clinical digital pathology, processing the highest volume of primary digital diagnosis nationwide. With over a decade of expertise, its innovative tissue-handling technology and AI-driven workflows set a new standard of efficiency, quality, and standardization in cancer diagnostics. Trusted by over
About Myriad Genetics
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company’s collaboration with Lumea will streamline the ordering and delivery of molecular tests and that by replacing manual processes, the integration will reduce errors and aims to provide clinicians with timely molecular testing results— on average, in under 10 days after specimen collection—to empower patients and providers to make informed decisions. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
_____________________________
i National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
FAQ
What is the expected turnaround time for MYGN's molecular test results through BxLink integration?
How many genes does MYGN's MyRisk Hereditary Cancer Test evaluate?
What are the two Myriad Genetics tests being integrated into Lumea's BxLink platform?
What is the main purpose of MYGN's Prolaris test in prostate cancer treatment?
